Enhancement of 2-arachidonoylglycerol but not anandamide signaling in the ventral tegmental area selectively increases the choice to respond to reward-predictive incentive cues in male rats.
Aug 2026· Neuropharmacology· pp.
111154
· 0 citations· 90 references
Medicine
TL;DR
The results suggest that increasing 2-AG, but not anandamide, in the VTA selectively enhances the choice to respond to cues predicting a reward, however, the effects of systemic MJN110 in enhancing the vigor of responding cannot be attributed to VTA 2-AG signaling.
Abstract
Mesolimbic endocannabinoid (eCB) signaling impacts reward-seeking behaviors that rely on incentive salience. We previously showed that systemic enhancement of 2-arachidonoylglycerol (2-AG) using the monoacylglycerol lipase (MAGL) inhibitor MJN110 robustly decreased the latency of responding to reward-predictive incentive cues (ICs) and collecting the reward, as well as the choice to respond to the IC. Here we sought to determine the contribution of the endocannabinoids 2-AG and anandamide in the ventral tegmental area (VTA) in mediating incentive salience processes. We microinfused MJN110 or PF3845, a fatty acid amide hydrolase (FAAH) inhibitor, into the VTA to increase 2-AG and anandamide, respectively in male rats. These rats were trained to nosepoke during an 8-sec audiovisual IC to receive a 10% sucrose reward. We found that while intra-VTA PF3845 had little effect on responding to the IC, intra-VTA MJN110 specifically increased only the choice to respond without impacting the vigor (e.g., rapidity) of the response towards either the IC or the sucrose reward itself. This contrasts with our previous work in which systemic MJN110 treatment enhanced choice, and vigor to both the IC and reward. Further, the intra-VTA MJN110 enhancement of responding to ICs was blocked by the CB1 receptor antagonist rimonabant. Our results suggest that increasing 2-AG, but not anandamide, in the VTA selectively enhances the choice to respond to cues predicting a reward. However, the effects of systemic MJN110 in enhancing the vigor of responding cannot be attributed to VTA 2-AG signaling.
A differential involvement of mPFC Orx2Rs in the acquisition and expression phases of CPP is proposed, suggesting distinguishable behavioral effects between food and morphine reward models, however, further mechanistic studies are required to clarify the underlying neural substrates.
S. Jamali, Mahboobeh Mirmohammadi, Ronak Azizbeigi et al.· Behavioural Brain Research· 0 citations
These findings suggest that NAcc D2-MSNs are recruited under conditions of environmental novelty to modulate feeding-related decision-making, and may impair behavioral flexibility and contribute to maladaptive feeding patterns, with implications for the neurobiology of eating disorders.
A. S. V. van Irsen, Tess Kool, Salimat Semenova et al.· Journal of Neuroscience· 0 citations
It is indicated that prior exposure to N-ADA can influence reward- and anxiety-related behaviors specifically under conditions of CB1 blockade/GPR55 modulation and an interaction with endocannabinoid signaling (or other rimonabant-sensitive mechanisms) is indicated.
Oliver A. Colis-Arenas, Katya Ch Navarro-Montellano, Carlos H. López-Lariz et al.· Physiology and Behavior· 0 citations
The lateral habenula (LHb) integrates cortical and basal forebrain (BF) input and is implicated in negative affective states, but its involvement in negative affect associated with cannabis withdrawal is unknown. Here, effects of withdrawal from the psychoactive cannabis constituent, Δ9-tetrahydrocannabinol (Δ9-THC), o...
Eun-Kyung Hwang, D. Daphne, Charlie C. Maddox et al.· Nature Communications· 0 citations
Inflammation is a primary response to injury. Here we show that inflammation plays a critical role in engaging the endocannabinoid system in the ventrolateral periaqueductal gray (vlPAG) to activate the descending pain modulatory circuit to inhibit pain. Inflammation-induced increases in corticosterone activate glucoco...
B. Coutens, C. Bouchet, I. Gvon et al.· Neuropsychopharmacology· 1 citation
The GLP-1-based obesity drug semaglutide lowers bodyweight primarily by increasing satiation and satiety, whilst also reducing food reward and commonly causing nausea. The brainstem dorsal vagal complex (DVC) has been identified as a key site of action for these phenotypic components of semaglutide’s anorectic effect....
Lauren A. Jones, Ella Cross, Yuqi Song et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.